Biogen Inc. Logo

Biogen Inc.

BIIB.SW

(2.2)
Stock Price

232,00 USD

9.68% ROA

7.92% ROE

28.98x PER

Market Cap.

30.035.922.456,00 USD

45.66% DER

0% Yield

12.07% NPM

Biogen Inc. Stock Analysis

Biogen Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Biogen Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (19.59%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a low debt to equity ratio (46%), which means it has a small amount of debt compared to the ownership it holds

4 PBV

The stock's PBV ratio (2.58x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

5 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (826), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Biogen Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Biogen Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

Biogen Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Biogen Inc. Revenue
Year Revenue Growth
1985 15.100.000
1986 6.400.000 -135.94%
1987 8.600.000 25.58%
1988 20.600.000 58.25%
1989 28.500.000 27.72%
1990 50.100.000 43.11%
1991 61.400.000 18.4%
1992 123.700.000 50.36%
1993 136.400.000 9.31%
1994 156.344.000 12.76%
1995 151.691.000 -3.07%
1996 277.090.000 45.26%
1997 434.044.000 36.16%
1998 557.587.000 22.16%
1999 794.435.000 29.81%
2000 926.452.000 14.25%
2001 1.043.360.000 11.2%
2002 1.148.364.000 9.14%
2003 679.183.000 -69.08%
2004 1.595.819.000 57.44%
2005 1.713.619.000 6.87%
2006 1.872.185.000 8.47%
2007 3.171.617.000 40.97%
2008 4.097.507.000 22.6%
2009 4.377.348.000 6.39%
2010 4.716.423.000 7.19%
2011 5.048.634.000 6.58%
2012 5.516.461.000 8.48%
2013 6.932.199.000 20.42%
2014 9.703.324.000 28.56%
2015 10.763.800.000 9.85%
2016 11.448.800.000 5.98%
2017 12.273.900.000 6.72%
2018 13.452.900.000 8.76%
2019 14.377.900.000 6.43%
2020 13.444.600.000 -6.94%
2021 10.981.700.000 -22.43%
2022 10.173.400.000 -7.95%
2023 10.121.200.000 -0.52%
2023 9.835.600.000 -2.9%
2024 9.162.000.000 -7.35%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Biogen Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 91.213.000 100%
1995 87.448.000 -4.31%
1996 132.384.000 33.94%
1997 145.501.000 9.02%
1998 177.228.000 17.9%
1999 221.153.000 19.86%
2000 302.840.000 26.97%
2001 314.556.000 3.72%
2002 367.567.000 14.42%
2003 1.056.337.000 65.2%
2004 687.663.000 -53.61%
2005 747.671.000 8.03%
2006 1.048.910.000 28.72%
2007 925.164.000 -13.38%
2008 1.072.058.000 13.7%
2009 1.283.068.000 16.45%
2010 1.248.604.000 -2.76%
2011 1.219.602.000 -2.38%
2012 1.334.919.000 8.64%
2013 1.444.053.000 7.56%
2014 1.893.422.000 23.73%
2015 2.012.800.000 5.93%
2016 1.973.300.000 -2%
2017 2.253.600.000 12.44%
2018 2.597.200.000 13.23%
2019 2.280.600.000 -13.88%
2020 3.990.900.000 42.85%
2021 2.501.200.000 -59.56%
2022 2.231.100.000 -12.11%
2023 2.945.200.000 24.25%
2023 2.462.000.000 -19.63%
2024 1.811.600.000 -35.9%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Biogen Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 2.295.500.000 100%
2020 2.392.700.000 4.06%
2021 2.575.600.000 7.1%
2022 2.349.500.000 -9.62%
2023 0 0%
2023 2.478.300.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Biogen Inc. EBITDA
Year EBITDA Growth
1985 -14.200.000
1986 -23.700.000 40.08%
1987 -18.600.000 -27.42%
1988 2.200.000 945.45%
1989 100.000 -2100%
1990 4.200.000 97.62%
1991 2.400.000 -75%
1992 32.800.000 92.68%
1993 27.900.000 -17.56%
1994 6.149.000 -353.73%
1995 18.361.000 66.51%
1996 56.093.000 67.27%
1997 168.264.000 66.66%
1998 234.783.000 28.33%
1999 360.115.000 34.8%
2000 525.929.000 31.53%
2001 426.410.000 -23.34%
2002 325.241.000 -31.11%
2003 -804.134.000 140.45%
2004 522.426.000 253.92%
2005 668.050.000 21.8%
2006 872.683.000 23.45%
2007 1.331.388.000 34.45%
2008 1.663.002.000 19.94%
2009 1.789.510.000 7.07%
2010 1.726.807.000 -3.63%
2011 2.070.889.000 16.62%
2012 2.252.735.000 8.07%
2013 3.026.995.000 25.58%
2014 4.642.376.000 34.8%
2015 5.404.500.000 14.1%
2016 5.882.800.000 8.13%
2017 6.329.600.000 7.06%
2018 7.073.500.000 10.52%
2019 7.518.700.000 5.92%
2020 4.807.300.000 -56.4%
2021 3.656.600.000 -31.47%
2022 2.686.100.000 -36.13%
2023 1.486.800.000 -80.66%
2023 2.598.900.000 42.79%
2024 2.932.000.000 11.36%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Biogen Inc. Gross Profit
Year Gross Profit Growth
1985 10.600.000
1986 -16.900.000 162.72%
1987 -12.400.000 -36.29%
1988 -500.000 -2380%
1989 3.300.000 115.15%
1990 14.700.000 77.55%
1991 18.100.000 18.78%
1992 121.500.000 85.1%
1993 130.900.000 7.18%
1994 146.396.000 10.58%
1995 141.187.000 -3.69%
1996 248.565.000 43.2%
1997 383.856.000 35.25%
1998 483.078.000 20.54%
1999 683.430.000 29.32%
2000 801.254.000 14.7%
2001 906.850.000 11.64%
2002 988.205.000 8.23%
2003 394.444.000 -150.53%
2004 1.041.500.000 62.13%
2005 1.340.005.000 22.28%
2006 1.597.802.000 16.13%
2007 2.836.425.000 43.67%
2008 3.695.518.000 23.25%
2009 3.995.244.000 7.5%
2010 4.316.161.000 7.44%
2011 4.581.854.000 5.8%
2012 4.970.967.000 7.83%
2013 6.074.473.000 18.17%
2014 8.532.288.000 28.81%
2015 9.523.400.000 10.41%
2016 9.970.100.000 4.48%
2017 10.643.900.000 6.33%
2018 11.636.600.000 8.53%
2019 12.422.500.000 6.33%
2020 11.639.400.000 -6.73%
2021 8.872.000.000 -31.19%
2022 7.895.100.000 -12.37%
2023 7.482.800.000 -5.51%
2023 7.302.200.000 -2.47%
2024 6.993.200.000 -4.42%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Biogen Inc. Net Profit
Year Net Profit Growth
1985 -19.100.000
1986 -28.200.000 32.27%
1987 -22.600.000 -24.78%
1988 -1.200.000 -1783.33%
1989 3.200.000 137.5%
1990 7.700.000 58.44%
1991 7.200.000 -6.94%
1992 38.300.000 81.2%
1993 32.400.000 -18.21%
1994 -4.897.000 761.63%
1995 5.660.000 186.52%
1996 40.530.000 86.04%
1997 89.167.000 54.55%
1998 138.697.000 35.71%
1999 220.450.000 37.08%
2000 333.577.000 33.91%
2001 272.683.000 -22.33%
2002 199.148.000 -36.92%
2003 -875.097.000 122.76%
2004 25.086.000 3588.39%
2005 160.711.000 84.39%
2006 217.511.000 26.11%
2007 638.172.000 65.92%
2008 783.167.000 18.51%
2009 970.132.000 19.27%
2010 1.005.273.000 3.5%
2011 1.234.428.000 18.56%
2012 1.380.033.000 10.55%
2013 1.862.341.000 25.9%
2014 2.934.784.000 36.54%
2015 3.547.000.000 17.26%
2016 3.702.800.000 4.21%
2017 2.539.100.000 -45.83%
2018 4.430.700.000 42.69%
2019 5.888.500.000 24.76%
2020 4.000.600.000 -47.19%
2021 1.556.100.000 -157.09%
2022 3.046.900.000 48.93%
2023 -272.400.000 1218.54%
2023 1.161.100.000 123.46%
2024 1.573.600.000 26.21%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Biogen Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 1 0%
2001 2 100%
2002 1 0%
2003 -5 125%
2004 0 0%
2005 0 0%
2006 1 0%
2007 2 100%
2008 3 0%
2009 3 33.33%
2010 4 0%
2011 5 40%
2012 6 0%
2013 8 28.57%
2014 12 41.67%
2015 15 20%
2016 17 6.25%
2017 12 -45.45%
2018 22 47.62%
2019 31 32.26%
2020 25 -29.17%
2021 10 -140%
2022 19 44.44%
2023 0 0%
2023 8 100%
2024 11 20%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Biogen Inc. Free Cashflow
Year Free Cashflow Growth
1989 -10.600.000
1990 -400.000 -2550%
1991 -2.500.000 84%
1992 33.700.000 107.42%
1993 36.800.000 8.42%
1994 -8.784.000 518.94%
1995 -40.860.000 78.5%
1996 -19.097.000 -113.96%
1997 62.082.000 130.76%
1998 134.234.000 53.75%
1999 185.961.000 27.82%
2000 166.824.000 -11.47%
2001 120.824.000 -38.07%
2002 45.522.000 -165.42%
2003 -82.035.000 155.49%
2004 358.223.000 122.9%
2005 571.127.000 37.28%
2006 642.956.000 11.17%
2007 736.529.000 12.7%
2008 1.288.538.000 42.84%
2009 909.252.000 -41.71%
2010 1.451.618.000 37.36%
2011 1.475.566.000 1.62%
2012 1.618.715.000 8.84%
2013 -1.163.922.000 239.07%
2014 2.654.364.000 143.85%
2015 3.073.100.000 13.63%
2016 3.794.700.000 19.02%
2017 2.588.200.000 -46.62%
2018 5.301.600.000 51.18%
2019 6.409.100.000 17.28%
2020 3.678.000.000 -74.26%
2021 3.345.000.000 -9.96%
2022 1.141.100.000 -193.14%
2023 1.235.800.000 7.66%
2023 504.800.000 -144.81%
2024 432.300.000 -16.77%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Biogen Inc. Operating Cashflow
Year Operating Cashflow Growth
1989 -7.500.000
1990 10.700.000 170.09%
1991 5.900.000 -81.36%
1992 43.100.000 86.31%
1993 47.600.000 9.45%
1994 34.886.000 -36.44%
1995 9.449.000 -269.2%
1996 46.539.000 79.7%
1997 97.632.000 52.33%
1998 167.845.000 41.83%
1999 272.288.000 38.36%
2000 365.939.000 25.59%
2001 316.358.000 -15.67%
2002 267.077.000 -18.45%
2003 219.213.000 -21.83%
2004 727.986.000 69.89%
2005 889.503.000 18.16%
2006 841.268.000 -5.73%
2007 1.020.635.000 17.57%
2008 1.564.492.000 34.76%
2009 1.074.898.000 -45.55%
2010 1.624.673.000 33.84%
2011 1.727.741.000 5.97%
2012 1.879.897.000 8.09%
2013 2.345.078.000 19.84%
2014 2.942.115.000 20.29%
2015 3.716.100.000 20.83%
2016 4.522.400.000 17.83%
2017 4.551.000.000 0.63%
2018 6.187.700.000 26.45%
2019 7.078.600.000 12.59%
2020 4.229.800.000 -67.35%
2021 3.639.900.000 -16.21%
2022 1.384.300.000 -162.94%
2023 1.547.200.000 10.53%
2023 592.400.000 -161.17%
2024 553.200.000 -7.09%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Biogen Inc. Capital Expenditure
Year Capital Expenditure Growth
1989 3.100.000
1990 11.100.000 72.07%
1991 8.400.000 -32.14%
1992 9.400.000 10.64%
1993 10.800.000 12.96%
1994 43.670.000 75.27%
1995 50.309.000 13.2%
1996 65.636.000 23.35%
1997 35.550.000 -84.63%
1998 33.611.000 -5.77%
1999 86.327.000 61.07%
2000 199.115.000 56.64%
2001 195.534.000 -1.83%
2002 221.555.000 11.74%
2003 301.248.000 26.45%
2004 369.763.000 18.53%
2005 318.376.000 -16.14%
2006 198.312.000 -60.54%
2007 284.106.000 30.2%
2008 275.954.000 -2.95%
2009 165.646.000 -66.59%
2010 173.055.000 4.28%
2011 252.175.000 31.38%
2012 261.182.000 3.45%
2013 3.509.000.000 92.56%
2014 287.751.000 -1119.46%
2015 643.000.000 55.25%
2016 727.700.000 11.64%
2017 1.962.800.000 62.93%
2018 886.100.000 -121.51%
2019 669.500.000 -32.35%
2020 551.800.000 -21.33%
2021 294.900.000 -87.11%
2022 243.200.000 -21.26%
2023 311.400.000 21.9%
2023 87.600.000 -255.48%
2024 120.900.000 27.54%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Biogen Inc. Equity
Year Equity Growth
1985 74.900.000
1986 89.300.000 16.13%
1987 67.900.000 -31.52%
1988 68.000.000 0.15%
1989 139.200.000 51.15%
1990 145.700.000 4.46%
1991 239.000.000 39.04%
1992 285.000.000 16.14%
1993 325.200.000 12.36%
1994 329.934.000 1.43%
1995 382.980.000 13.85%
1996 484.370.000 20.93%
1997 536.293.000 9.68%
1998 718.613.000 25.37%
1999 979.530.000 26.64%
2000 1.106.402.000 11.47%
2001 1.348.832.000 17.97%
2002 1.595.421.000 15.46%
2003 7.053.328.000 77.38%
2004 6.826.401.000 -3.32%
2005 6.905.876.000 1.15%
2006 7.149.778.000 3.41%
2007 5.534.295.000 -29.19%
2008 5.806.083.000 4.68%
2009 6.221.530.000 6.68%
2010 5.396.506.000 -15.29%
2011 6.425.499.000 16.01%
2012 6.961.523.000 7.7%
2013 8.620.242.000 19.24%
2014 10.809.010.000 20.25%
2015 9.372.800.000 -15.32%
2016 12.140.100.000 22.79%
2017 12.612.800.000 3.75%
2018 13.039.600.000 3.27%
2019 13.335.000.000 2.22%
2020 10.671.900.000 -24.95%
2021 11.023.200.000 3.19%
2022 13.378.900.000 17.61%
2023 14.475.600.000 7.58%
2023 14.799.400.000 2.19%
2024 15.213.000.000 2.72%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Biogen Inc. Assets
Year Assets Growth
1985 85.800.000
1986 100.900.000 14.97%
1987 80.700.000 -25.03%
1988 80.900.000 0.25%
1989 145.200.000 44.28%
1990 158.500.000 8.39%
1991 253.100.000 37.38%
1992 311.200.000 18.67%
1993 357.000.000 12.83%
1994 377.862.000 5.52%
1995 469.201.000 19.47%
1996 634.572.000 26.06%
1997 813.825.000 22.03%
1998 924.715.000 11.99%
1999 1.277.973.000 27.64%
2000 1.431.856.000 10.75%
2001 1.721.046.000 16.8%
2002 2.006.988.000 14.25%
2003 9.503.945.000 78.88%
2004 9.165.758.000 -3.69%
2005 8.366.947.000 -9.55%
2006 8.552.808.000 2.17%
2007 8.628.815.000 0.88%
2008 8.478.991.000 -1.77%
2009 8.551.854.000 0.85%
2010 8.092.493.000 -5.68%
2011 9.049.604.000 10.58%
2012 10.127.846.000 10.65%
2013 11.862.739.000 14.62%
2014 14.311.529.000 17.11%
2015 19.504.800.000 26.63%
2016 22.876.800.000 14.74%
2017 23.652.600.000 3.28%
2018 25.288.900.000 6.47%
2019 27.234.300.000 7.14%
2020 24.618.900.000 -10.62%
2021 23.877.300.000 -3.11%
2022 24.554.100.000 2.76%
2023 28.193.200.000 12.91%
2023 26.844.800.000 -5.02%
2024 26.567.600.000 -1.04%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Biogen Inc. Liabilities
Year Liabilities Growth
1985 10.900.000
1986 11.600.000 6.03%
1987 12.800.000 9.38%
1988 12.900.000 0.78%
1989 6.000.000 -115%
1990 12.800.000 53.13%
1991 14.100.000 9.22%
1992 26.200.000 46.18%
1993 31.800.000 17.61%
1994 47.928.000 33.65%
1995 86.221.000 44.41%
1996 150.202.000 42.6%
1997 277.532.000 45.88%
1998 206.102.000 -34.66%
1999 298.443.000 30.94%
2000 325.454.000 8.3%
2001 372.214.000 12.56%
2002 411.567.000 9.56%
2003 2.450.617.000 83.21%
2004 2.339.357.000 -4.76%
2005 1.461.071.000 -60.11%
2006 1.403.030.000 -4.14%
2007 3.094.520.000 54.66%
2008 2.672.908.000 -15.77%
2009 2.289.972.000 -16.72%
2010 2.643.050.000 13.36%
2011 2.622.617.000 -0.78%
2012 3.166.323.000 17.17%
2013 3.242.497.000 2.35%
2014 3.502.519.000 7.42%
2015 10.129.900.000 65.42%
2016 10.748.200.000 5.75%
2017 11.054.500.000 2.77%
2018 12.257.300.000 9.81%
2019 13.895.200.000 11.79%
2020 13.932.800.000 0.27%
2021 12.917.600.000 -7.86%
2022 11.165.700.000 -15.69%
2023 13.713.500.000 18.58%
2023 12.045.400.000 -13.85%
2024 11.354.600.000 -6.08%

Biogen Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
66.32
Net Income per Share
8.01
Price to Earning Ratio
28.98x
Price To Sales Ratio
3.11x
POCF Ratio
20.55
PFCF Ratio
23.39
Price to Book Ratio
2.22
EV to Sales
3.72
EV Over EBITDA
14.74
EV to Operating CashFlow
21.83
EV to FreeCashFlow
27.96
Earnings Yield
0.03
FreeCashFlow Yield
0.04
Market Cap
30,04 Bil.
Enterprise Value
35,91 Bil.
Graham Number
137.15
Graham NetNet
-51.63

Income Statement Metrics

Net Income per Share
8.01
Income Quality
1.41
ROE
0.08
Return On Assets
0.04
Return On Capital Employed
0.09
Net Income per EBT
0.88
EBT Per Ebit
0.65
Ebit per Revenue
0.21
Effective Tax Rate
0.12

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0.24
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.75
Operating Profit Margin
0.21
Pretax Profit Margin
0.14
Net Profit Margin
0.12

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
11.29
Free CashFlow per Share
8.82
Capex to Operating CashFlow
-0.22
Capex to Revenue
-0.04
Capex to Depreciation
-0.68
Return on Invested Capital
0.08
Return on Tangible Assets
0.1
Days Sales Outstanding
75.53
Days Payables Outstanding
58.54
Days of Inventory on Hand
380.73
Receivables Turnover
4.83
Payables Turnover
6.23
Inventory Turnover
0.96
Capex per Share
-2.48

Balance Sheet

Cash per Share
7,37
Book Value per Share
104,41
Tangible Book Value per Share
4.81
Shareholders Equity per Share
104.41
Interest Debt per Share
49.42
Debt to Equity
0.46
Debt to Assets
0.26
Net Debt to EBITDA
2.41
Current Ratio
2.1
Tangible Asset Value
0,70 Bil.
Net Current Asset Value
-4,60 Bil.
Invested Capital
0.46
Working Capital
3,53 Bil.
Intangibles to Total Assets
0.55
Average Receivables
2,05 Bil.
Average Payables
0,40 Bil.
Average Inventory
2522100000
Debt to Market Cap
0.23

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Biogen Inc. Dividends
Year Dividends Growth

Biogen Inc. Profile

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

CEO
Mr. Christopher A. Viehbacher
Employee
7.570
Address
225 Binney Street
Cambridge, 02142

Biogen Inc. Executives & BODs

Biogen Inc. Executives & BODs
# Name Age
1 Dr. Ginger Gregory Ph.D.
Executive Vice President & Chief Human Resources Officer
70
2 Mr. Christopher A. Viehbacher
President, Chief Executive Officer & Director
70
3 Mr. Michael R. McDonnell CPA
Executive Vice President & Chief Financial Officer
70
4 Ms. Nicole Murphy
Head of Pharmaceutical Operations & Technology
70
5 Ms. Robin C. Kramer
Senior Vice President & Chief Accounting Officer
70
6 Mr. Adam Keeney Ph.D.
Executive Vice President & Head of Corporate Development
70
7 Ms. Susan H. Alexander Esq.
Executive Vice President & Chief Legal Officer
70
8 Mr. Rachid Izzar
Head of Global Product Strategy & Commercialization
70
9 Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corporate Affairs
70
10 Mr. Charles E. Triano
Senior Vice President & Head of Investor Relations
70

Biogen Inc. Competitors